miRNAs represent promising therapeutic candidates for targeting BCSCs through coordinated regulation of proliferation, resistance, and metastatic behaviour. However, the translational advancement of miRNA-based strategies requires more standardized experimental frameworks, expanded in vivo studies, and deeper mechanistic investigation to ensure safety and efficacy across breast cancer subtypes.
Ting et al. (Sun,) studied this question.